Osteoclast Inhibitory Lectin (OCIL), an immune cell product that is required for normal bone physiology in vivo
Vicky Kartsogiannis(Monash Institute of Medical Research), Matthew T. Gillespie(Hudson Institute of Medical Research), C. Hai Ly(St Vincents Institute of Medical Research), Ingrid J. Poulton(St Vincents Institute of Medical Research), H. Saleh(The University of Melbourne), Mark J. Smyth(Peter MacCallum Cancer Centre), Natalie A. Sims(The University of Melbourne), Morgan E. Wallace(Peter MacCallum Cancer Centre), Mirijana Cipetić(St Vincents Institute of Medical Research), T. John Martin(St Vincent's Hospital Melbourne), J Quinn(The University of Melbourne), Narelle E. McGregor(St. Vincent's Medical Center), Hong Zhou(California NanoSystems Institute), K.W. Ng(St Vincent's Hospital Melbourne), Emma C. Walker(Washington University in St. Louis)
Cited by 2
Related Papers
Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families
|Endocrine Reviews|1999|2.3k
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
|Journal of Clinical Investigation|1999|1.7k
Immune surveillance of tumors
|Journal of Clinical Investigation|2007|1.4k
Tumor Necrosis Factor α Stimulates Osteoclast Differentiation by a Mechanism Independent of the Odf/Rankl–Rank Interaction
|The Journal of Experimental Medicine|2000|1.3k